DIRECTLY ACTING ANTI-VIRAL DRUGS AND ITS METABOLIC SIDE EFFECTS IN PATIENTS WITH CHRONIC HC

Abstract

HCV infection is a major cause of liver cirrhosis, (HCC) and end-stage liver disease. The development of an interferon-free, all-oral treatment regimen represents an important advance. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) with or without Ribavirin in chronic HCV patients. Results Sustained virological response (12 weeks ) after end of the treatment in more than 90% of patients , Liver function parameters including albumin, bilirubin, and prothrombin time and liver enzymes Ast , Alt improved in the majority of patients during and after the end of therapy ,but there is significant increase in urea level , serum creatinin and HbA1C. There is significant decrease in LDL and mild increase in TG level. Conclusion Once-daily oral daclatasvir plus sofosbuvir with or without Ribavirin was associated with high rates of sustained virologic response among patients infected with HCV , including chronic cirrhotic patients and relapsers , successful treatment associated with Improvement of liver functio